# Ketamine and Esketamine for Depression
## Pharmacology
### Mechanism of Action
**NMDA receptor antagonism:** blocks the N-methyl-D-aspartate glutamate receptor, particularly at GABAergic interneurons. Blockade of NMDA receptors on inhibitory interneurons leads to a paradoxical "glutamate burst" -- increased glutamate release onto AMPA receptors on pyramidal neurons. AMPA receptor activation triggers downstream signaling cascades: BDNF release, mTOR pathway activation, rapid synaptic protein synthesis. Result: rapid synaptogenesis and restoration of synaptic connections in prefrontal cortex and hippocampus -- the "synaptogenic hypothesis". This mechanism is fundamentally different from monoaminergic antidepressants and explains the rapid onset (hours vs. weeks)
### Ketamine vs. Esketamine
| Feature | IV Ketamine (Racemic) | Intranasal Esketamine (Spravato) |
|---------|----------------------|----------------------------------|
| Composition | S + R enantiomers | S-enantiomer only |
| Route | Intravenous | Intranasal |
| FDA Status | Off-label for depression | Approved for TRD (2019) and acute suicidality in MDD (2020) |
| NMDA Affinity | Moderate (mixed) | ~4x higher than R-ketamine |
| Dosing | 0.5 mg/kg over 40 min | 56-84 mg per session |
| Onset | Minutes | 20-40 minutes |
| Monitoring | Variable (no REMS) | 2-hour REMS observation required |
| Cost | Lower (~$400-800/infusion) | Higher (~$5,000-6,000/month initial) |
| Setting | Ketamine clinics (unregulated) | REMS-certified facilities only |
**Ketamine:** racemic mixture of S-ketamine and R-ketamine; administered IV (off-label for depression) **Esketamine (Spravato):** the S-enantiomer; administered intranasally; FDA-approved for treatment-resistant depression (TRD) and MDD with acute suicidal ideation/behavior (2019, 2020) S-ketamine has ~4x higher affinity for the NMDA receptor than R-ketamine. R-ketamine may have its own antidepressant properties through non-NMDA mechanisms (under investigation) Ketamine also acts at opioid receptors, sigma receptors, HCN1 channels, and monoamine transporters.
### Pharmacokinetics
IV ketamine: onset within minutes; antidepressant effects peak at 24 hours; typical duration of single-dose effect 3-7 days. Intranasal esketamine: bioavailability ~48%; peak plasma levels at 20-40 minutes. Metabolized by CYP3A4 and CYP2B6 to norketamine (active metabolite) Half-life: ketamine ~2.5 hours; esketamine ~7-12 hours (including metabolites)
## Clinical Evidence
### IV Ketamine for Depression
**Zarate et al. 2006:** landmark crossover RCT; single IV ketamine infusion (0.5 mg/kg over 40 minutes) produced rapid antidepressant effects within 2 hours in TRD. Multiple RCTs confirm rapid-onset antidepressant effects; response rates 50-70% at 24 hours post-infusion. Effects of single infusions are transient (typically 3-7 days) Serial infusion protocols (e.g., 6 infusions over 2-3 weeks) produce more sustained effects. No FDA approval for IV ketamine in depression; used off-label in ketamine clinics.
### Intranasal Esketamine (Spravato)
**TRANSFORM trials (1, 2, 3):** phase III RCTs in treatment-resistant depression. TRANSFORM-1 and TRANSFORM-3 showed significant improvement vs. placebo. TRANSFORM-2: mixed results; not all doses significant. **SUSTAIN trials:** long-term relapse prevention; esketamine + oral antidepressant significantly delayed relapse vs. oral antidepressant alone. **ASPIRE trials:** rapid reduction in suicidal ideation/behavior in MDD patients with acute suicidality (led to second FDA indication) FDA-approved dosing: 56-84 mg intranasally, initially twice weekly for 4 weeks, then weekly for 4 weeks, then weekly or biweekly.
### Acute Suicidality Indication
One of the only medications shown to rapidly reduce suicidal ideation (within hours) ASPIRE I and II trials demonstrated superiority over placebo for MADRS suicidal ideation item. Does not replace hospitalization or comprehensive suicide risk assessment.
## REMS Program and Administration
### Risk Evaluation and Mitigation Strategy (REMS)
Esketamine is available ONLY through a restricted distribution system (Spravato REMS) Must be administered in a certified healthcare facility under direct supervision. Patient self-administers the nasal spray under clinician observation. Patients must be monitored for at least 2 hours after each administration. Assessment includes: blood pressure monitoring (risk of transient hypertension), sedation level, dissociative symptoms, suicidality assessment.
### Administration Protocol
Patient should avoid food for 2 hours and liquids for 30 minutes before dosing. Nasal spray devices: each device delivers 28 mg (2 sprays); doses of 56 mg (2 devices) or 84 mg (3 devices) Must be used in conjunction with a newly initiated oral antidepressant. Patients must not drive or operate machinery until the day after treatment.
## Adverse Effects and Safety Concerns
### Acute Effects
**Dissociation:** most common; derealization, depersonalization, perceptual disturbances; typically peaks at 40 minutes and resolves within 2 hours. **Sedation:** drowsiness, dizziness; resolves within 2 hours in most patients. **Hypertension:** transient increase in blood pressure (mean ~7-9 mmHg systolic); contraindicated in uncontrolled hypertension, aneurysmal vascular disease. **Nausea/vomiting:** ~25-30% of patients. **Headache:** common, usually mild.
### Safety Controversies
**Abuse potential:** ketamine is a Schedule III controlled substance with known recreational misuse; esketamine REMS was designed to mitigate this risk. **Long-term safety:** limited data beyond 1 year; concerns about: Neurocognitive effects with repeated dosing (ketamine neurotoxicity in animal models at high doses) Urological toxicity (interstitial cystitis) reported in chronic recreational users; not observed at clinical doses in trials. Hepatic effects: transient LFT elevations reported. **Durability of response:** unclear how long treatment should continue; relapse is common upon discontinuation. **Opioid system involvement:** naltrexone pretreatment may block ketamine's antidepressant effect (Williams et al. 2018), suggesting opioid receptor involvement -- raises concerns about potential for psychological dependence.
### Access and Equity Concerns
Cost: esketamine is expensive (~$5,000-6,000 per month initially); insurance coverage variable. REMS requirements create logistical barriers (travel to certified centers, 2-hour monitoring) IV ketamine clinics are largely out-of-pocket and unregulated. Raises equity concerns: rapid-acting treatment for severe depression accessible mainly to affluent patients.
A mechanism of action diagram showing how ketamine produces rapid antidepressant effects. Illustrate the synapse with: (1) NMDA receptor blockade on GABAergic interneurons, (2) disinhibition leading to glutamate burst, (3) AMPA receptor activation on pyramidal neurons, (4) downstream BDNF release and mTOR pathway activation, (5) rapid synaptogenesis and dendritic spine growth. Compare this with a parallel panel showing the slow monoaminergic mechanism of traditional antidepressants (weeks for receptor desensitization and BDNF changes). Neuroscience illustration style with molecular detail.
A timeline comparison of antidepressant onset of action. Show three horizontal timelines: SSRI/SNRI (onset 2-4 weeks, full effect 6-8 weeks), ketamine IV single dose (onset 2 hours, peak 24 hours, waning by day 7), and esketamine serial dosing (onset hours, accumulating benefit over 4-week induction, maintenance phase). Label response and remission thresholds. Include annotation showing the "gap" that ketamine fills for acute suicidality and treatment-resistant depression. Clean clinical timeline format.
An infographic showing the esketamine REMS administration workflow. Steps include: patient arrives at certified facility, pre-dose assessment (BP, suicidality screen, fasting status), self-administration of nasal spray under supervision, 2-hour monitoring period with BP checks at 40 minutes, 1 hour, and 2 hours, post-monitoring assessment (dissociation, sedation, vitals), discharge with instructions not to drive. Include dose schedule (twice weekly for weeks 1-4, weekly for weeks 5-8, then weekly or biweekly maintenance). Clean process flow diagram.
## Clinical Pearls
Ketamine/esketamine represents the first truly novel mechanism of antidepressant action in decades -- glutamatergic rather than monoaminergic. The rapid onset of action (hours vs. weeks) makes ketamine/esketamine uniquely valuable for patients with acute suicidality who cannot wait for traditional antidepressants to take effect. Esketamine is approved only as an adjunct to oral antidepressants, not as monotherapy. Dissociation during administration is common and expected -- counsel patients in advance; it is generally not distressing when patients are prepared. IV ketamine and intranasal esketamine are not interchangeable -- different formulations, regulatory status, dosing, and evidence bases. The opioid system involvement in ketamine's antidepressant mechanism remains controversial and has implications for patients with concurrent opioid use disorder. Long-term treatment planning is essential -- there is no established endpoint for esketamine, and relapse rates upon discontinuation are significant.
## References
- Zarate CA Jr, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry*. 2006;63(8):856-864.
- Daly EJ, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. *JAMA Psychiatry*. 2018;75(2):139-148.
- FDA. Spravato (esketamine) REMS. 2019. https://www.spravatorems.com
- Krystal JH, et al. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. *Neuropsychopharmacology*. 2024;49:41-50.
- Williams NR, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. *Am J Psychiatry*. 2018;175(12):1205-1215.
- Fu DJ, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent (ASPIRE I and II). *J Clin Psychiatry*. 2020;81(3):19m13191.